• Silence Therapeutics reported positive topline Phase 2 SANRECO results for divesiran in phlebotomy-dependent polycythemia vera, supporting a best-in-class positioning.
• The trial met its main efficacy goal, showing most treated patients maintained hematocrit control without needing phlebotomy versus placebo.
• Secondary measures also improved, including reduced phlebotomy use, better iron markers, and symptom scores.
• Safety was consistent with earlier studies, with no new safety signals reported.
• Full data will be presented at a future medical congress; Phase 3 development is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260810915756) on August 10, 2026, and is solely responsible for the information contained therein.